<DOC>
	<DOCNO>NCT02580253</DOCNO>
	<brief_summary>This study randomize , open-label , control study explore efficacy individualize adjuvant chemotherapy base adenosine triphosphate tumor chemosensitivity assay patient hepatocellular carcinoma liver transplantation .</brief_summary>
	<brief_title>Adjuvant Chemotherapy Based Adenosine Triphosphate Tumor Chemosensitivity Assay Hepatocellular Carcinoma After Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>Patients experience liver transplantation histologically confirm advanced hepatocellular carcinoma one risk factor ( tumour burden &gt; 8 cm , AFP &gt; 400 ng/mL , poorly differentiate , vessel invasion ) No extrahepatic metastasis confirm compute tomography ( CT ) magnetic resonance imaging ( MRI ) Additional inclusion criterion age 18 year old Karnofsky performance status ( KPS ) least 70 % Adequate renal function , define creatinine clearance great 30 mL/min ) Adequate hepatic function , define ALT AST le 5× upper limit normal Adequate bone marrow function , define platelet great 100×10E9/L WBC great 3.5×10E9/L . The presence severe concomitant disease could interrupt plan treatment ; intractable pain Hypersensitivity study drug Serious cardiovascular disease ( eg , unstable coronary artery disease myocardial infarction within 4 week study start ) National Cancer Institute CommonToxicity Criteria ( NCICTC ) grade 3 4 sensory motor neuropathy Prior concurrent malignancy ( pancreatic cancer ) Female , pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>